Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s Disease
March 14, 2023 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
– Composition of matter patent from USPTO covers more than 100 novel compounds targeting neurodegenerative diseases including Alzheimer’s – – Newly patented compounds and legacy asset PBT2 licensed...
Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial
February 16, 2023 16:44 ET
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy
January 25, 2023 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia AND SAN FRANCISCO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Amydis Awarded $3 Million NIH Grant to Explore Novel Alpha Synuclein Retinal Tracer in Non-human Primate Models of Parkinson’s Disease and Multiple System Atrophy
October 11, 2021 07:00 ET
|
Amydis, Inc.
SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...
Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer for the Diagnosis of Alpha-synucleinopathies
April 26, 2021 07:00 ET
|
Amydis, Inc.
SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer biotechnology company with a broad portfolio of diagnostic candidates for detection of neurodegenerative diseases...
Multiple System Atrophy Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade
January 13, 2021 18:30 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Multiple System Atrophy Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade Multiple System Atrophy Clinical Trial Analysis...
Amydis Awarded Michael J. Fox Foundation Grant to Accelerate Development of an Alpha-Synuclein Retinal Tracer to Diagnose Parkinson’s Disease Through the Eye
August 11, 2020 07:00 ET
|
Amydis, Inc.
SAN DIEGO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Amydis, Inc., a biotechnology company developing a new class of diagnostics to enable the early detection of neurological diseases through the retina,...